AZ’ Fasenra gets US nod for eosinophilic asthma

15th November 2017 Uncategorised 0

AstraZeneca’s biologic Fasenra has picked up its first global approval in the US as a treatment for severe, eosinophilic asthma, a difficult to treat form of the condition.

More: AZ’ Fasenra gets US nod for eosinophilic asthma
Source: News